Lobbying in Washington is booming to record-high levels, and companies are rushing to hire Trump-allied firms in their efforts to influence the policy pronouncements spilling out of the White House. Overall, federal lobbying spending is up by 21% compared with last year, according to the Washington Post’s tally of expenditures through the third quarter of 2025. In the surge, the firm of Trump campaign fundraiser Brian Ballard has become the highest-paid lobbying shop, and other Trump-aligned firms are seeing an influx of clients as trade and tariff policies churn.
The pharmaceutical industry has juiced its lobbying spending: heavyweight PhRMA is certain to blow past its record high in lobbying spending set last year. The nearly $29.7 million the drugmakers’ group has spent through Q3 approaches the amount that it spent in all of 2024. Health industry lobbyists are weighing in on moves by the Trump administration and the GOP-led Congress to cut Medicaid funding and fire staffers in the overhaul of the Robert F. Kennedy Jr.-led Department of Health and Human Services.
Over the summer, the Trump administration sent letters to 17 companies behind brand-name drugs demanding they lower costs by a Sept. 29 deadline. It was followed by President Trump’s threat of 100% tariffs on branded imported drugs, a threat the administration is not yet enforcing.
